DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
NB-001 is an investigational drug.
There have been 5 clinical trials for NB-001. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Herpes Labialis, Glaucoma, and Herpes Simplex. The leading clinical trial sponsors are NanoBio Corporation, Danube Pharmaceuticals, Inc., and [disabled in preview].
Recent Clinical Trials for NB-001
|NB-001 Treatment of Recurrent Herpes Labialis||NanoBio Corporation||Phase 3|
|A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis||NanoBio Corporation||Phase 3|
|A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)||NanoBio Corporation||Phase 3|
Top disease conditions for NB-001
Top clinical trial sponsors for NB-001
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|NB-001||Canada||CA2625553||2025-10-14||⤷ Free Forever Trial|
|NB-001||China||CN1947717||2025-10-14||⤷ Free Forever Trial|
|NB-001||European Patent Office||EP1948182||2025-10-14||⤷ Free Forever Trial|
|NB-001||Japan||JP2009511508||2025-10-14||⤷ Free Forever Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|